Arcus Biosciences (RCUS) Cash from Financing Activities (2017 - 2026)

Arcus Biosciences' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 97.89% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $349.0 million (up 83.68% YoY), while the FY2025 annual figure was $488.0 million, up 76.17% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $3.0 million, down from $286.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $286.0 million in Q4 2025, with the low at -$2.0 million in Q4 2024.
• The 5-year median for Cash from Financing Activities is $8.0 million (2025), against an average of $49.1 million.
• Peak annual rise in Cash from Financing Activities reached 22800.0% in 2024, while the deepest fall reached 166.67% in 2024.
• Arcus Biosciences' Cash from Financing Activities stood at $11.0 million in 2022, then slumped by 72.73% to $3.0 million in 2023, then plunged by 166.67% to -$2.0 million in 2024, then soared by 14400.0% to $286.0 million in 2025, then plunged by 98.95% to $3.0 million in 2026.
• Business Quant data shows RCUS's Cash from Financing Activities at $3.0 million in Q1 2026, $286.0 million in Q4 2025, and $8.0 million in Q3 2025.